“Expert Clinical Framework Report: Management of Adverse Events Related to Novel Therapies for Relapsed Refractory Multiple Myeloma (RRMM)”. Canadian Hematology Today, vol. 1, no. S11, Nov. 2022, https://doi.org/10.58931/cht.2022.1S1130.